AgriMedysis Corporation Launches a micro dosing psychedelic mushroom-based extract that will help people with pain

HAWKESBURY, Ontario, Feb. 18, 2022 /PRNewswire-PRWeb/ -- AgriMedysis Corporation. (the "Company" or "AgriMedysis") AgriMedysis is advancing in psychedelic and medicinal mushroom research & development. We are targeting novel pharmaceutical formulations as we are focused on:

• AgriMedysis is launching through pharmaceutical collaboration (psychedelic mushroom based) clinical trials and products into jurisdictions where AgriMedysis is not a banned substance. Jurisdictions include Jamaica, Netherlands & Brazil.
• Structuring a large IP portfolio around key indications, delivery mechanism, infusion & emulsification processes, and extraction methods for the pharmaceutical sector.
• Research has found that certain medicinal mushrooms may protect against dementia, reduce mild symptoms of anxiety and depression, and help repair nerve damage. Certain mushroom species may also have strong immune-boosting abilities and have shown the ability to lower the risk of heart disease, cancer, ulcers, and diabetes in animals.
• Medicinal mushrooms may stimulate innate immune cells, such as monocytes, natural killer cells, and dendritic cells.
• Medicinal mushrooms have been examined in-depth in clinical studies and many of their health benefits have been proven although much more studies need to be conducted on humans to fully unlock their potential
• Sales of medicinal mushrooms through nutraceutical form factors are 100% legal globally and the overall market is expected to exceed US$7B in sales annually by 2025
• AgriMedysis has developed a method for Isolation, Identification and Standardization of API. Our validation of yield for water-solvent extract vs other technics and a library of leads: Psilocybin, Psilocin, tryptamine, alkaloids.

About AgriMedysis Corporation.

AgriMedysis specializes in the contract services, commercialization, and development of evidence-based consume products for the healthcare, fungi, psilocybin, and organic markets.

For more information, visit: http://www.agrimedysis.com

Forward-looking statements Some statements in this release may contain forward-looking information. All statements, other than statements of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by the use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include the Company's inability to obtain sufficient financing to execute its business plan; competition; regulation; anticipated and unanticipated costs and delays; the success of the Company's research and development strategies; the ability to obtain orphan drug status; the applicability of the discoveries made; the successful and timely completion and uncertainties related to the regulatory approval process; the timing of future clinical trials; the timing and outcomes of regulatory or intellectual property decisions; and other risks disclosed in the Company's public disclosure record on file with the relevant regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this news release, and the Company does not undertake any obligation to publicly update them to reflect new information or subsequent events or otherwise except as required by applicable securities legislation.

For more information:

AgriMedysis Corporation.
Leo Stella (Investor Relation)
[email protected]
tel: 1 -866 351 4141

SOURCE AgriMedysis Corporation